Clover Health Investments Crop. ($CLOV) Stock Forecast: Down 5.8% Today

What is Clover Health Investments Crop.?

Clover Health (CLOV) operates in the healthcare technology sector, specifically offering Medicare Advantage plans for elderly individuals in the US. The stock has experienced notable fluctuations lately, particularly showing a strong downward trend today.

Why is Clover Health Investments Crop. going down?

CLOV stock is down 5.8% on Jun 12, 2026 16:01

• Today's decline in CLOV's stock price could be linked to the significant sale of CLOV common stock by CEO Jamie Reynoso. This sale may have raised concerns among investors regarding the company's future outlook.
• The disposal of 7,289 shares by Reynoso, although a minor portion of her total holdings, might have indicated skepticism about the current valuation of the stock.
• Furthermore, the analysis suggesting that the stock is presently overpriced could have intensified the selling pressure and contributed to the downward movement.
• Investors could view this insider transaction as a warning sign, fostering pessimism towards CLOV and pushing its stock price downward.

CLOV Price Chart

CLOV Technical Analysis

CLOV News

Clover Health CEO Jamie Reynoso sells $35,788 of CLOV common stock

Clover Health Investments Corp. CEO Jamie L. Reynoso sold 7,289 shares of CLOV common stock for approximately $35,788 on June 11, 2026. This transaction occurred via a pre-arranged trading plan, with shares sold at prices between $4.79 and $5.15. The sale happened as the stock was near its 52-week high after a 108% year-to-date return, while InvestingPro analysis suggests the stock is currently overvalued.

https://www.investing.com/news/insider-trading-news/clover-health-ceo-jamie-reynoso-sells-35788-of-clov-common-stock-93CH-4738700

Clover Health (NASDAQ: CLOV) exec sells 7,289 shares under 10b5-1 plan

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health (NASDAQ: CLOV), sold 7,289 shares of Class A Common Stock at a weighted average price of $4.91 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following the transaction, Reynoso directly retains 2,849,921 shares, indicating the sale represents a small portion of her overall holdings.

https://www.stocktitan.net/sec-filings/CLOV/form-4-clover-health-investments-corp-de-insider-trading-activity-36b17b827766.html

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 17.4% Today

Clover Health Investments Crop. Price History

22.03.2026 - CLOV Stock was up 5.2%

• The positive sentiment surrounding CLOV stock today may be linked to executives having shares withheld for tax obligations related to the vesting of restricted stock units (RSUs), signaling confidence in the company's future growth.
• Tax-related share withholding actions by top executives, including the CEO, CFO, and Chief Legal Officer, may have bolstered investor trust in the leadership team's dedication to long-term success, boosting investor confidence and elevating the stock price.
• These transactions reflect transparency and adherence to tax regulations, potentially boosting the company's reputation and credibility with investors and stakeholders, fueling the bullish market movement in CLOV stock today.

19.04.2026 - CLOV Stock was up 5.0%

• The interim CFO of Clover Health, Joseph Clay, had a portion of his RSUs withheld for tax obligations, suggesting positive sentiments about the company's future outlook.
• Fidelity Investments' SEC filing to sell a significant number of shares had a neutral impact on the market, indicating that this action might not be perceived negatively by market participants.
• Despite CEO Brady Patrick Priest selling a substantial amount of shares, analysts continue to forecast profitability for the company this year, potentially bolstering investor confidence.
• The CEO's insider selling of shares, though initially causing some negativity, did not deter investors, potentially highlighting a focus on the company's growth prospects.

21.03.2026 - CLOV Stock was up 10.2%

• The bullish movement in CLOV's stock today is possibly influenced by executives' decision to withhold shares for tax obligations relating to the vesting of restricted stock units (RSUs), showcasing confidence in the company's future performance.
• Routine tax-related dispositions by key executives, including the CEO, CFO, and Chief Legal Officer, reflect their dedication to Clover Health's long-term success, likely bolstering investor confidence.
• These transactions could be seen as a positive display of transparency and sound financial management, potentially contributing to the upward momentum in CLOV's stock price.
• Overall, the market's favorable reaction to the executives' actions hints at their trust in Clover Health's growth potential and financial stability.

15.04.2026 - CLOV Stock was down 5.3%

• The decrease in CLOV's stock price could be linked to the CEO, Brady Patrick Priest, selling a considerable number of shares, potentially indicating uncertainties or lacking confidence within the company.
• Furthermore, the insider selling disclosed in Form 4 filings by both CEO Brady Patrick Priest and CEO Andrew Toy may have triggered concerns among investors, resulting in diminished market trust and a subsequent drop in the stock value.
• Despite analysts forecasting profitability for the ongoing year, the stock's perception of being slightly overvalued, as highlighted in InvestingPro's analysis, might have also played a role in fostering negative sentiment and downward pressure on CLOV's shares.

03.05.2026 - CLOV Stock was down 5.9%

• Today's downward movement in CLOV stock can be linked to several factors:
• A class action lawsuit alleging false and misleading statements and the withholding of vital information has potentially shaken investor confidence, prompting a sell-off.
• CEO Conrad Wai engaging in significant insider selling of company stock near its 52-week high could have indicated doubt about the company's future prospects.
• Despite the insider sales, Conrad Wai still holds a substantial stake in the company, raising concerns about potential future sales impacting the stock.
• Mixed Q1 2026 earnings were reported, with revenue exceeding forecasts but EPS falling short, potentially fueling negative sentiment around the stock.

07.04.2026 - CLOV Stock was up 5.8%

• The bullish movement in CLOV could be attributed to investors gaining confidence in the company's ability to navigate through the ongoing securities class action lawsuit.
• Despite the legal challenges, the market seems to be optimistic about Clover Health's future prospects and potential for growth in the healthcare technology sector.
• Investors might be reassured by the company's response to the allegations and its efforts to address any concerns raised by the Department of Justice investigation and related-party deals.
• The upcoming deadline for the lead plaintiff in the securities class action lawsuit could also be driving increased interest and trading activity in CLOV as investors position themselves based on potential outcomes.

02.05.2026 - CLOV Stock was down 5.0%

• The decline in CLOV stock may be linked to the CEO, Conrad Wai, selling a substantial amount of company stock, totaling $879k. This noteworthy insider selling activity could have sparked concerns among investors regarding the company's future prospects.
• The sale of 220,426 shares by the CEO, particularly when the stock was near its 52-week high, might have indicated to investors that insiders perceive the stock as possibly overvalued.
• Furthermore, the mixed Q1 2026 earnings report, where revenue surpassed expectations but EPS fell short, could have also played a role in the negative sentiment surrounding the stock. Investors may have responded unfavorably to the earnings shortfall despite the strong revenue performance.

13.04.2026 - CLOV Stock was up 5.3%

• A tax-related share withholding transaction took place on May 8, 2026, where CEO Andrew Toy withheld 85,704 shares to meet tax obligations. This action might have suggested a positive outlook on the company's future.
• The scheduled quarterly vesting of remaining restricted stock units (RSUs) until August 8, 2026, could have instilled confidence among investors, signaling a strong commitment from the leadership.
• The insider activity, including the aforementioned transactions, likely bolstered shareholder confidence and drew in new investors, influencing CLOV's stock price surge today.

29.04.2026 - CLOV Stock was down 5.6%

• Insider selling: A notable planned sale of shares by a company officer potentially conveyed doubts about the company's future, possibly influencing investor pessimism.
• Rule 10b5-1 trading plan: The implementation of the sale through a pre-arranged trading arrangement might have reinforced negative market perceptions, suggesting a deliberate strategy to divest shares.
• Market reaction: Investors likely viewed the insider selling as a warning sign, prompting a sell-off of CLOV stock and contributing to the day's downward trend.

14.04.2026 - CLOV Stock was up 7.5%

• The bullish movement in CLOV's stock price today may have been influenced by CEO Brady Patrick Priest's sale of shares, which could have boosted investor confidence in the company's future.
• Analysts' positive predictions of profitability for the current year might have contributed to the upward trend in CLOV's stock price, despite concerns about its valuation.
• The recent insider selling of shares by CEO Priest, disclosed in a Form 4 filing, initially raised concerns of insider trading but the market focus appears to have shifted towards the company's positive outlook.
• CEO Andrew Toy's routine share withholding transaction for tax purposes did not seem to have a significant impact on CLOV's market performance today, with investors likely more swayed by profitability forecasts and CEO Priest's share sale.

09.05.2026 - CLOV Stock was up 8.9%

• The bullish movement in CLOV's stock price could be attributed to investors' optimism or positive sentiment surrounding the company despite the ongoing legal challenges.
• The reminders and deadlines for investors to join the class action lawsuits may have already been factored into the stock price, leading to a less significant impact on the market movement.
• Investors may be focusing more on the potential growth prospects and technological innovations of Clover Health rather than the legal issues.
• It's possible that some traders are viewing the current legal challenges as temporary hurdles for the company, leading to increased buying interest and driving the stock price higher.

12.05.2026 - CLOV Stock was down 5.8%

• Today's decline in CLOV's stock price could be linked to the significant sale of CLOV common stock by CEO Jamie Reynoso. This sale may have raised concerns among investors regarding the company's future outlook.
• The disposal of 7,289 shares by Reynoso, although a minor portion of her total holdings, might have indicated skepticism about the current valuation of the stock.
• Furthermore, the analysis suggesting that the stock is presently overpriced could have intensified the selling pressure and contributed to the downward movement.
• Investors could view this insider transaction as a warning sign, fostering pessimism towards CLOV and pushing its stock price downward.